Cynata Therapeutics Limited (CYYNF)
USD 0.3
(117.39%)
USD 0.3
(117.39%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -12.26 Million AUD | 24.58% |
| 2023 | -16.26 Million AUD | -19.95% |
| 2022 | -13.55 Million AUD | -54.06% |
| 2021 | -8.8 Million AUD | 13.99% |
| 2020 | -10.23 Million AUD | -4.61% |
| 2019 | -9.78 Million AUD | -67.17% |
| 2018 | -5.85 Million AUD | 3.33% |
| 2017 | -6.05 Million AUD | -2.57% |
| 2016 | -5.9 Million AUD | -54.75% |
| 2015 | -3.81 Million AUD | -21.16% |
| 2014 | -3.14 Million AUD | -244.06% |
| 2013 | -914.72 Thousand AUD | 18.84% |
| 2012 | -1.12 Million AUD | 55.74% |
| 2011 | -2.54 Million AUD | -21.1% |
| 2010 | -2.1 Million AUD | -47.39% |
| 2009 | -1.42 Million AUD | 3.43% |
| 2008 | -2.02 Million AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -5.25 Million AUD | 0.0% |
| 2024 Q1 | -2.2 Million AUD | 76.0% |
| 2024 Q2 | -6.94 Million AUD | -215.67% |
| 2024 FY | - AUD | 24.58% |
| 2023 FY | - AUD | -19.95% |
| 2023 Q1 | -2.51 Million AUD | 50.05% |
| 2023 Q3 | -4.78 Million AUD | 29.94% |
| 2023 Q4 | -9.17 Million AUD | -91.55% |
| 2023 Q2 | -6.83 Million AUD | -171.57% |
| 2022 Q3 | -2.39 Million AUD | -134.12% |
| 2022 Q2 | -1.02 Million AUD | -106.68% |
| 2022 FY | - AUD | -54.06% |
| 2022 Q1 | -495.6 Thousand AUD | 88.42% |
| 2022 Q4 | -5.03 Million AUD | -110.08% |
| 2021 Q2 | -4.81 Million AUD | -101.15% |
| 2021 Q1 | -2.39 Million AUD | 33.07% |
| 2021 FY | - AUD | 13.99% |
| 2021 Q3 | -1.23 Million AUD | 74.43% |
| 2021 Q4 | -4.28 Million AUD | -247.41% |
| 2020 Q4 | -3.57 Million AUD | -872.56% |
| 2020 Q1 | -1.24 Million AUD | 77.34% |
| 2020 FY | - AUD | -4.61% |
| 2020 Q2 | -6.93 Million AUD | -458.22% |
| 2020 Q3 | -367.92 Thousand AUD | 94.69% |
| 2019 Q1 | -1.48 Million AUD | -6.06% |
| 2019 Q2 | -1.48 Million AUD | 0.0% |
| 2019 FY | - AUD | -67.17% |
| 2019 Q4 | -5.48 Million AUD | -99.27% |
| 2019 Q3 | -2.75 Million AUD | -85.29% |
| 2018 Q4 | -1.4 Million AUD | 0.0% |
| 2018 Q2 | -837.85 Thousand AUD | 0.0% |
| 2018 Q1 | -837.85 Thousand AUD | 51.04% |
| 2018 FY | - AUD | 3.33% |
| 2018 Q3 | -1.4 Million AUD | -67.1% |
| 2017 Q4 | -1.71 Million AUD | 0.0% |
| 2017 FY | - AUD | -2.57% |
| 2017 Q1 | -440.69 Thousand AUD | 64.36% |
| 2017 Q3 | -1.71 Million AUD | -288.29% |
| 2017 Q2 | -440.69 Thousand AUD | 0.0% |
| 2016 FY | - AUD | -54.75% |
| 2016 Q2 | -1.16 Million AUD | 0.0% |
| 2016 Q1 | -1.16 Million AUD | 0.21% |
| 2016 Q4 | -1.23 Million AUD | 0.0% |
| 2016 Q3 | -1.23 Million AUD | -6.24% |
| 2015 Q3 | -1.27 Million AUD | -80.21% |
| 2015 Q4 | -1.16 Million AUD | 8.76% |
| 2015 Q2 | -709.31 Thousand AUD | 0.0% |
| 2015 Q1 | -709.31 Thousand AUD | -3.55% |
| 2015 FY | - AUD | -21.16% |
| 2014 Q4 | -684.99 Thousand AUD | 0.0% |
| 2014 Q3 | -684.99 Thousand AUD | 21.81% |
| 2014 Q2 | -876.07 Thousand AUD | 0.0% |
| 2014 Q1 | -876.08 Thousand AUD | -293.3% |
| 2014 FY | - AUD | -244.06% |
| 2013 Q4 | -222.74 Thousand AUD | 0.0% |
| 2013 FY | - AUD | 18.84% |
| 2013 Q3 | -222.74 Thousand AUD | 0.0% |
| 2012 FY | - AUD | 55.74% |
| 2011 FY | - AUD | -21.1% |
| 2010 FY | - AUD | -47.39% |
| 2009 FY | - AUD | 3.43% |
| 2008 FY | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Qrons Inc. | -40.08 Thousand USD | -30500.734% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 113.043% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 2425.429% |
| Adynxx, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 22.714% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -600.862% |
| BioStem Technologies, Inc. | -7.55 Million USD | -62.373% |
| CSL Limited | 4.78 Billion USD | 100.256% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -215.759% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 29.389% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 77.836% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1209.045% |
| Skye Bioscience, Inc. | -13.54 Million USD | 9.466% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -3239.972% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1189.703% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1839.431% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 82.734% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -106.869% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -5028.614% |
| SQZ Biotechnologies Company | -64.14 Million USD | 80.878% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -363.805% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -698.482% |
| Mesoblast Limited | -62.38 Million USD | 80.341% |
| Marizyme, Inc. | -34.28 Million USD | 64.222% |
| Genus plc | 73.7 Million USD | 116.642% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -85.511% |
| Pharming Group N.V. | 9.87 Million USD | 224.178% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -724.592% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -245.788% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -39.821% |
| ContraFect Corporation | -64.99 Million USD | 81.13% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -170.98% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -774.947% |
| IMV Inc. | -35.52 Million USD | 65.473% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -427.798% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -2267.566% |
| ONE Bio Corp. | 13.61 Million USD | 190.098% |
| Accustem Sciences Inc. | -3.74 Million USD | -227.381% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 74.568% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -867.94% |
| Q BioMed Inc. | -617.62 Thousand USD | -1885.836% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 443.367% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -436.885% |
| Biomind Labs Inc. | -1.03 Million USD | -1085.548% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 69.056% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -324.056% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -71.27% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 182507.496% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -48960.32% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -390.218% |
| GB Sciences, Inc. | -1.41 Million USD | -763.808% |
| Alpha Cognition Inc. | -9.7 Million USD | -26.371% |
| HST Global, Inc. | -5303.00 USD | -231185.687% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -496.261% |
| Halberd Corporation | -74.27 Thousand USD | -16412.177% |
| Enzolytics Inc. | -2.12 Million USD | -477.988% |
| Agentix Corp. | -1.37 Million USD | -794.115% |
| Resverlogix Corp. | -11.74 Million USD | -4.455% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -300.425% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 94.322% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1107.813% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 238.529% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -718.269% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 3337.501% |
| AVAX Technologies, Inc. | -6.11 Million USD | -100.651% |
| Zenith Capital Corp. | -8.6 Million USD | -42.518% |
| Genscript Biotech Corporation | -248.71 Million USD | 95.069% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -70303.995% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -401.34% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -6867.831% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -538.503% |
| Kadimastem Ltd | -2.62 Million USD | -367.351% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1072.22% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -6672.994% |
| LadRx Corporation | 412.28 Thousand USD | 3074.918% |
| Cell Source, Inc. | -4.27 Million USD | -187.069% |
| Regen BioPharma, Inc. | 1.46 Million USD | 936.661% |
| NovAccess Global Inc. | -1.03 Million USD | -1085.264% |
| Affymax, Inc. | -14.29 Million USD | 14.2% |
| Itoco Inc. | -1.86 Million USD | -556.239% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -3130.884% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -999.022% |
| Mobile Lads Corp. | -2.24 Million USD | -447.265% |
| CytoDyn Inc. | -18.02 Million USD | 31.97% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -15419.721% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -100195.036% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -2425.352% |
| SYBLEU INC | -141.57 Thousand USD | -8563.554% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1054.893% |
| International Stem Cell Corporation | 202 Thousand USD | 6171.822% |
| Bioxytran, Inc. | -3.82 Million USD | -221.063% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -23199.924% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -398.189% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 65.806% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -27155.733% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -347.958% |
| Neutra Corp. | -181.24 Thousand USD | -6667.053% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 39.158% |
| PureTech Health plc | -11.62 Million USD | -5.488% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 39.154% |
| IXICO plc | -707 Thousand USD | -1634.806% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -59.598% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 74.631% |
| CSL Limited | 4.73 Billion USD | 100.259% |
| Cellectis S.A. | -92.63 Million USD | 86.76% |